惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

D
DataBreaches.Net
MongoDB | Blog
MongoDB | Blog
GbyAI
GbyAI
L
LangChain Blog
B
Blog
博客园 - 三生石上(FineUI控件)
Martin Fowler
Martin Fowler
博客园 - 【当耐特】
Recent Announcements
Recent Announcements
P
Proofpoint News Feed
U
Unit 42
Last Week in AI
Last Week in AI
WordPress大学
WordPress大学
有赞技术团队
有赞技术团队
雷峰网
雷峰网
Microsoft Security Blog
Microsoft Security Blog
T
The Blog of Author Tim Ferriss
爱范儿
爱范儿
小众软件
小众软件
I
InfoQ
G
Google Developers Blog
大猫的无限游戏
大猫的无限游戏
人人都是产品经理
人人都是产品经理
C
Check Point Blog

Company News: Companies Analysis, Updates & Insights | The HinduBusinessLine

Boiler blast at Vedanta plant in Chhattisgarh kills 11, injures 22 Madhya Pradesh CM says basmati rice from the State is exported to 47 nations IMD forecast of below-normal Indian monsoon poses risk to agriculture, economy Sify data centre arm IPO on track and will be timed with market conditions, says CFO BALCO deploys AI humanoid agent for real-time training, operations and safety Funskool clocks $40 million revenue in FY26, despite tariff headwinds Val-Met Engineering secures ₹200 crore funding from Nuvama Crossover Opportunities Funds BEML secures $36.38 million export order from West Asia region Chitale Bandhu Mithaiwale to inaugurate new production facility near Pune NCLT allows personal guarantee case against Videocon promoter Dhoot No immediate impact of US blocking Iranian vessels on India’s crude cargoes Indian spacetech startups shift gears from R&D to scalable manufacturing Protest by factory workers in Noida, Faridabad turns violent Sharon Pais takes over as Head of Myntra Nadir Godrej to retire as chairperson, Pirojsha Godrej named successor APAC emerges as growth engine amid data sovereignty push: IBM’s Hans Dekkers Unicharm India expands Diabetes Care portfolio Sarovar Hotels sees traction in tier II cities, pilgrimage towns Motherson Sumi Wiring says no impact on operations amid Noida labour protests Aster DM Healthcare invests ₹96 cr to expand Aster Whitefield by 159 beds Ola Electric launches S1 X+ 5.2 kWh with 4680 Bharat Cells India’s active LED display market hits ₹2,000 crore China’s TCL is said to consider stake sale in India TV business Strengthening R&D, investment key for Indian drugmakers to lead globally: Nadda Piper Serica deploys ₹210 crore in 33 start-ups; to invest remaining ₹63 crore in 2-3 months NCLAT adjourns hearing on Vedanta plea against selection of Adani's bid for JAL GE Aerospace signs contract with Indian Air Force to help establish in-country depot for F404-IN20 engines RateGain launches AI-driven hotel marketing certification programme Q4 Results This Week: HDFC Bank, ICICI Bank, Wipro, Just Dial among 42 companies reporting GE Aerospace scales AI from pilots to production; India anchors global capability
Fredun enters high-value hormone therapeutics segment wit...
2026-05-17 · via Company News: Companies Analysis, Updates & Insights | The HinduBusinessLine
Fredun Medhora, Managing Director, Fredun Pharmaceuticals

Fredun Medhora, Managing Director, Fredun Pharmaceuticals

Fredun Pharmaceuticals has launched “Hormone Range Products,” a premium speciality therapeutics brand focused on longevity, hormone health, recovery science and human performance solutions.

The move marks Fredun’s strategic entry into a rapidly expanding, high-value healthcare segment driven by increasing global demand for preventive, performance-oriented, and precision-based therapeutics.

Built on a doctor-led, ethical and evidence-backed pharmaceutical model, the hormone range products combine clinical credibility with a digital-first patient and doctor engagement ecosystem to deliver an integrated healthcare experience focused on outcomes, adherence, and long-term patient value.

Shift towards preventive and performance-based healthcare

The range is designed to address the growing shift from traditional disease management to healthy lifespan optimisation, preventive care, and advanced performance therapeutics, the company said.

The initial portfolio includes therapies and formulations based on testosterone and its salts, nandrolone, growth hormone-oriented solutions and supportive hormone optimisation therapies, developed to meet specialised clinical requirements under appropriate medical supervision. The platform is further supported by protocol-driven patient monitoring, doctor engagement, and direct-to-patient fulfilment capabilities designed to improve treatment continuity and patient adherence.

Leveraging pharma expertise for premium therapeutics growth

The brand leverages Fredun Pharmaceuticals’ established strengths in pharmaceutical formulation development, quality-focused manufacturing and global distribution capabilities, while creating new opportunities in premium, innovation-driven therapeutic segments.

With increasing consumer and medical focus on vitality, metabolic health, recovery science, and preventive wellness, Fredun believes its hormone range products are well-positioned to address an evolving market opportunity through a trusted, outcomes-focused, and ethically driven pharmaceutical approach.

Management vision for high-science healthcare expansion

Fredun Medhora, Managing Director, Fredun Pharmaceuticals, said as the company moves up the value chain, the focus will be on entering segments that demand high scientific rigour, clinical validation and manufacturing excellence.

The product range reflects the company’s vision to bring medical expertise and evidence-based formulations together for creating a credible presence in hormone and performance therapeutics, he added.

Published on May 16, 2026